Showing 6761-6770 of 7641 results for "".
- BTL Aesthetics To Unveil New Ultra Femme 360° Technology for Vaginal Rejuvenation at AADhttps://practicaldermatology.com/news/btl-aesthetics-to-unveil-new-ultra-femme-360-technology-for-vaginal-rejuvenation-at-aad/2458263/BTL Industries is introducing its new 360° technology to leading cosmetic dermatologists and physicians during the annual American Academy of Dermatology (AAD) Conference taking place in Orlando, FL, March 3rd – 7th, with th
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th
- Modernizing Medicine and Galderma Team Up to Offer Integrated OTC eCommerce Platformhttps://practicaldermatology.com/news/modernizing-medicine-and-galderma-team-up-to-offer-integrated-otc-ecommerce-platform/2458264/Specialty-specific health information technology company Modernizing Medicine, Inc. and Galderma Laboratories, L.P. are collaborating to deliver new capabilities in support of improved patient experiences and outcomes through healthcare provider recommended over-
- DermMentors™ 2017 Resident of Distinction Award Honors Five Dermatology Residentshttps://practicaldermatology.com/news/dermmentors-2017-resident-of-distinction-award-honors-five-dermatology-residents/2458273/As part of the dermMentors™ Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 16th Annual Caribbean Dermatology Symposium in Aruba, Netherlands Antilles, from January 17 - 21, 2017
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- New From Skinceuticals: H.A. Intensifierhttps://practicaldermatology.com/news/new-from-skinceuticals-ha-intensifier/2458285/SkinCeuticals is rolling out their new H.A. Intensifier, a corrective hyaluronic acid serum. Key ingredients include 10% Proxylane, a proprietary ingredient, to support hyaluronic acid levels and
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- New From Alastin Skincare: HydraTint ProMineral Broad Spectrum Sunscreen SPF 36https://practicaldermatology.com/news/new-from-alastin-skincare-hydratint-promineral-broad-spectrum-sunscreen-spf-36/2458289/ALASTIN Skincare, Inc. is introducing HydraTint ProMineral Broad Spectrum Sunscreen SPF 36. The lightweight matte formula is oil-free, absorbs quickly and has a tint. It also comprises an air pollution shield to protect skin from environmental aggresso
- Intramuscular Flu Shots May Mitigate Staph Risk In AD Patientshttps://practicaldermatology.com/news/intramuscular-flu-shots-may-be-better-for-ad-patients/2458290/Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu vaccines may be more effective in this group. The research, funded by the Natio
- Allergan to Acquire ZELTIQ for $2.47 Billionhttps://practicaldermatology.com/news/allergan-to-acquire-zeltiq-for-247-billion/2458291/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary